Additional file 1: Table S1. of Cardiovascular risk is similar in patients with glomerulonephritis compared to other types of chronic kidney disease: a matched cohort study

The biomarker hazard ratios using Cox proportional hazards models that included GN vs non-GN CKD and each biomarker individually. ACR, CRP, IL-6, ProBNP and FGF-23 were log-transformed for analysis. (DOCX 15 kb

sj-docx-1-cjk-10.1177_20543581241228731 – Supplemental material for Oral Nutritional Supplement Prescription and Patient-Reported Symptom Burden Among Patients With Late-Stage Non-Dialysis Chronic Kidney Disease

Supplemental material, sj-docx-1-cjk-10.1177_20543581241228731 for Oral Nutritional Supplement Prescription and Patient-Reported Symptom Burden Among Patients With Late-Stage Non-Dialysis Chronic Kidney Disease by Michelle M. Y. Wong, Yuyan Zheng, Bingyue Zhu, Lee Er, Mohammad Atiquzzaman, Alexandra Romann, Dani Renouf, Zainab Sheriff and Adeera Levin in Canadian Journal of Kidney Health and Disease</p

sj-docx-1-cjk-10.1177_20543581231160511 – Supplemental material for Determining the Longitudinal Serologic Response to COVID-19 Vaccination in the Chronic Kidney Disease Population: A Clinical Research Protocol

Supplemental material, sj-docx-1-cjk-10.1177_20543581231160511 for Determining the Longitudinal Serologic Response to COVID-19 Vaccination in the Chronic Kidney Disease Population: A Clinical Research Protocol by Kevin Yau, Omosomi Enilama, Adeera Levin, Marc G. Romney, Joel Singer, Peter Blake, Jeffrey Perl, Jerome A. Leis, Robert Kozak, Hubert Tsui, Shelly Bolotin, Vanessa Tran, Christopher T. Chan, Paul Tam, Miten Dhruve, Christopher Kandel, Jose Estrada-Codecido, Tyler Brown, Aswani Siwakoti, Kento T. Abe, Queenie Hu, Karen Colwill, Anne-Claude Gingras, Matthew J. Oliver and Michelle A. Hladunewich in Canadian Journal of Kidney Health and Disease</p

Existence of a national strategy for NCDs.

Numbers represent countries (%).</p

Existence of a national strategy for NCDs.

(EPS)</p

(A) Existence and (B) type of CKD-specific policies.

(EPS)</p

Existence of a national strategy for improving CKD care.

(EPS)</p

Government recognition as a priority (A) and availability of an advocacy group (B) for AKI, CKD, and kidney failure treatment and prevention.

Government recognition as a priority (A) and availability of an advocacy group (B) for AKI, CKD, and kidney failure treatment and prevention.</p